Okyo Pharma shares surge 10.89% premarket on favorable Phase 2 corneal nerve regeneration data for urcosimod in neuropathic corneal pain trials.

OKYO Pharma surged 10.89% in premarket trading following the release of positive Phase 2 clinical trial data for its drug candidate urcosimod. The company reported that patients treated with 0.05% urcosimod demonstrated directionally favorable improvements in corneal nerve fiber count and length, as measured by in vivo confocal microscopy, compared to the placebo group. These results, described as "highly encouraging" by the principal investigator, suggest urcosimod may not only reduce neuropathic corneal pain but also support nerve regeneration, reinforcing its potential as a first-in-class therapy for a condition lacking FDA-approved treatments. The exploratory data, while non-statistically significant (p=0.057), highlight the drug’s promise and align with OKYO’s plans to initiate a larger multicenter trial in Q1 2026.